Chemical biology

Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors

Retrieved on: 
Mercoledì, Maggio 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Scripps Research, American Academy, Faculty, Biology, Royal, Bayer, Education, Heart, Stanford University, B.A, Searle, Therapy, Disease, Physiology, Biochemistry, National academy, Chemical biology, National Academy of Medicine, Searle Scholars Program, Drug discovery, Gene, TSRI, Medicine, Wolf Prize in Chemistry, Royal Society, History, Wolf Prize, Scripps, Pharmaceutical industry

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.

Key Points: 
  • Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.
  • Dr. Cravatt is professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute.
  • “By combining genuine expertise across biology, chemistry and genetics, Ben has pioneered an approach to drug discovery and development that sits at the heart of Actio’s mission,” said David Goldstein, Ph.D., co-founder and CEO of Actio.
  • He received a Ph.D. from The Scripps Research Institute (TSRI) in 1996 and joined the faculty at TSRI in 1997.

Nextworld Welcomes Barry Rowan to Executive Advisory Board

Retrieved on: 
Giovedì, Maggio 9, 2024
College of Idaho, Harvard Business School, Chemical biology, CFO, Business administration, College, Management

DENVER, May 9, 2024 /PRNewswire/ -- Nextworld, a leading provider of enterprise software solutions, proudly announces the addition of Barry Rowan to its Executive Advisory Board.

Key Points: 
  • DENVER, May 9, 2024 /PRNewswire/ -- Nextworld, a leading provider of enterprise software solutions, proudly announces the addition of Barry Rowan to its Executive Advisory Board.
  • "Barry Rowan's addition to our Executive Advisory Board is an exciting announcement for Nextworld," said Kylee McVaney, CEO of Nextworld.
  • "I am honored to join Nextworld's Executive Advisory Board," said Barry Rowan.
  • For more information about Nextworld and its Executive Advisory Board, please visit nextw.com/advisory-board .

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Giovedì, Marzo 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Martedì, Febbraio 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Ferroptosis, Immunology, Cameron Boyce, Broad Institute, Drug discovery, Autoimmune disease, Science, Virology, Janssen Pharmaceuticals, Research, Chemical biology, MIT, Dana–Farber Cancer Institute, Apoptosis, Conditional sentence, Yale School of Medicine, Bayer, Yang, Therapy, Cancer, Investment, Polaris Partners, ARIAD Pharmaceuticals, Medicine, Harvard University, Yale New Haven Hospital, Scripps Research, Patient, Cardiovascular disease, Colgate University, Harvard Medical School, Organization, Yale school, Wolf Prize, Pharmaceutical industry

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

Retrieved on: 
Lunedì, Novembre 27, 2023
Drug resistance, UKRI, Cellular senescence, Metastasis, Nature Cell Biology, Protein, Medicine, ICS, Research, Chemical biology, Imperial College London, Spacecraft, COPI, CRUK, NMT, ARF1, Cancer, GSK, Notifiable disease, Laboratory, Inflammation, Cell, Phenotype, Medical school, Data, ADC, Francis Crick Institute

Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.

Key Points: 
  • Senescent, or so called ‘zombie’ cells, can have deleterious effects on tissue function as they are persistent and secrete many proteins.
  • Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.
  • Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells.
  • Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Giovedì, Settembre 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute for Materials Research and Testing, Pharmaceutical industry, Fine chemical, Nursing, Spexy Beast

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Key Points: 
  • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Giovedì, Settembre 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute of Science and Technology, Fine chemical, Pharmaceutical industry, Nursing, Spexy Beast

ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Key Points: 
  • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Wistar-Led Team Awarded More Than $12 Million Grant from the NCI to Investigate Link Between Epstein-Barr Virus and Carcinomas

Retrieved on: 
Mercoledì, Luglio 26, 2023
Infection, Life, Collaborative writing, Cancer, Harvard University, Epithelium, P01, Epstein–Barr virus, Research, Ellen, Malignancy, National Cancer Institute, Translational medicine, Gene expression, Wistar Institute, Metabolomics, Lymphoma, Drug discovery, Tempera, Chemical biology, NCI, Carcinoma, Virus, EBV, Pharmaceutical industry, Wistar

The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers.

Key Points: 
  • The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers.
  • The new research will focus on basic questions about how EBV infection of normal epithelial cells transforms them into cancer-cells.
  • It’s the first time researchers from this variety of disciplines have combined their efforts to focus entirely on the EBV-epithelial cancer link.
  • Tempera said the group’s integrated approach sets it apart.“Our project will study both metabolic and epigenetic vulnerabilities simultaneously,” he said.

BullFrog AI Announces Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence

Retrieved on: 
Martedì, Luglio 11, 2023
Pharmacy, BS, Broad Institute, Drug development, University, University of Puerto Rico School of Dental Medicine, Harvard University, Biomedical Research, Intelligence, Research, Biomedical sciences, MIT, ROME, Machine learning, Synovial sarcoma, Engineering, Medicine, Artificial intelligence, National Institute for Interdisciplinary Science and Technology, Therapy, Chemical biology, Bullfrog, Medical device

GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence.

Key Points: 
  • GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence.
  • The appointment will further advance BullFrog AI’s best-in-class proprietary bfLEAP™ AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design of clinical trials to speed safe and effective drug development.
  • “We are excited to welcome Enrique to BullFrog AI.
  • His vast experience in developing machine learning models and managing large biological databases further augments BullFrog AI’s industry-leading capabilities.